Navigation Links
Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
Date:1/3/2008

UPPSALA, Sweden, January 3 /PRNewswire/ -- Amic AB (Uppsala, Sweden) announced today that is has been granted a non-exclusive license under patent rights of Roche Diagnostics to commercialise a point-of-care (POC) test for NT-proBNP on the European market.

NT-proBNP is a key cardiac marker for a broad array of cardiovascular conditions, including the diagnosis and management of heart failure, and risk stratification of patients with acute coronary syndrome.

"This agreement with Roche Diagnostics marks a major milestone in Amic's development. The NT-proBNP test will be one of the first to be launched on our Forecast POC diagnostic system. The market for NT-proBNP testing is growing significantly in Europe, and we see great potential in the future for monitoring and managing the treatment of heart failure patients at the point of care," says Lars Gunneflo, CEO, Amic AB.

About Amic AB

Amic is a privately held POC diagnostic company with R&D and manufacture facilities based in Uppsala, Sweden. The company is developing the next generation of POC diagnostic tests using its proprietary microfluidic technology. The technology uses a moulded plastic device called the 4castchip(R), and a state-of-the-art optical detection system for precise and sensitive quantification of immunoassays.

The Company intends to launch the Forecast POC Diagnostic System with high-performance test kits for the cardiac markers NT-proBNP and cTnI.

The marker specific test cartridge contains the 4castchip(R) in a user friendly format for rapid analysis of whole-blood patient samples at the point of care. The Forecast Reader is a low-cost analyser designed for fail-safe operation in hospital and primary care settings with full connectivity to laboratory informations systems.

For more information please visit the company website at http://www.amic.se


'/>"/>
SOURCE Amic AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
2. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Monsanto Company Signs Share Subscription Agreement With Devgen
5. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
6. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
7. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
8. Assay Designs(TM) Announces Additions to the Leadership Team
9. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
Breaking Biology News(10 mins):